7 in 10 Digestive Cancer Patients Were Already Malnourished — and the Support Program Built to Help Fell Short

7 in 10 Digestive Cancer Patients Were Already Malnourished — and the Support Program Built to Help Fell Short

The chemotherapy has not even started yet, and the weight is already going.

Ten pounds since the diagnosis. Then fifteen. Meals get smaller — a few bites and the plate feels finished. Clothes hang differently. The oncologist calls it "some weight loss, which is common with this cancer," and everyone moves on to the treatment plan.

But in digestive cancers — cancers of the pancreas, stomach, esophagus, colon, and bile ducts — that weight loss is often not a side note. It is one of the main threats to whether treatment can be given at full strength at all.

So one French cancer center decided to do something systematic about it. Instead of waiting for patients to struggle, the team at Institut Curie built a Nutritional Frailty Score to flag the patients most at risk, then offered them a structured support program: a dietitian, a physiotherapist, and a palliative care doctor, on a set schedule alongside chemotherapy.

On November 5, 2026, the team published what happened in Scientific Reports — two studies, called ParcoursDig and PrePOP, covering patients starting first-line chemotherapy and patients heading into major surgery.

The findings are sobering. In the surgical group, about 7 in 10 patients (71%) were already malnourished before treatment began — and nearly a third of those were severely malnourished. And in the support-program group, fewer than half of patients — 44% — managed to complete the full program, far short of the 80% completion bar the researchers had set for themselves.

This is not a story about a program that failed because nobody cared. It is a story about how hard it is to actually deliver supportive care to very sick people — and what these researchers say has to change.

What Is Nutritional Frailty?

"Malnutrition" sounds simple — not eating enough. In digestive oncology, it is rarely that simple.

Malnutrition in cancer means the body is not getting, absorbing, or keeping enough nutrients to maintain its tissue — especially its muscle. Doctors typically flag it when they see things like:

• Unplanned weight loss — more than 5% of body weight in one month, or 10% in six months
• A low body mass index (BMI) for age
• Measurable loss of muscle mass or strength
• Eating much less than usual, because of symptoms, blockage, pain, or poor absorption

"Frailty" adds the bigger picture: how much reserve a person has left. A frail patient may be older, carrying other illnesses, struggling with symptoms, and losing ground nutritionally — all at once. Any one of those can be managed. Stacked together, they shrink the margin for error with every chemotherapy cycle.

That is why the Institut Curie team combined them into one number. Their Nutritional Frailty Score pulls together a patient's age, their day-to-day functioning (what oncologists call performance status), their other medical conditions, and their baseline nutritional status, to estimate who is most likely to deteriorate nutritionally once treatment starts.

The point of a score like this is triage. Support teams are small. Dietitian appointments are scarce. A score says: start here, with this patient, now — instead of waiting until the weight loss is impossible to ignore.

In the surgical study, 71% of patients were malnourished before treatment — and 31% of those were severely malnourished. The problem is not rare. It is the norm.

One honesty note before we go further: the score is new, built by this one center, and the authors state plainly that it has not yet been validated against standard criteria in other hospitals or larger groups. It is a promising tool being tested, not a proven one.

Offering Support Is Not the Same as Delivering It

Here is the assumption this study quietly dismantles: if a cancer center offers good supportive care, patients will receive good supportive care.

It sounds obvious. A patient is flagged as high-risk. Appointments are booked with the dietitian, the physiotherapist, and the palliative care doctor. The plan is in the chart. Surely the support happens.

Think of it like a gym membership in January. Owning the membership is not the workout. Between the plan and the result sits real life: feeling too sick to travel, a scan running late, a hospital ward closed by a virus wave, a body that is simply too tired that week.

For people in the middle of chemotherapy for advanced digestive cancer, "real life" is heavier still. Their disease is progressing or stable at best. Their energy is rationed. Every appointment competes with treatment itself.

The ParcoursDig study is valuable precisely because it measured the gap between the plan and the reality — and reported it honestly, even though the gap made the program look bad.

How Digestive Cancers Drain Nutrition and Muscle

Why are these cancers so punishing nutritionally? Several mechanisms stack up at once.

The tumor sits in the machinery

Digestive cancers grow in the organs that do the eating and absorbing. A stomach tumor can make a normal meal feel impossible. A pancreatic tumor can block the enzymes that digest fat and protein. An esophageal tumor can make swallowing itself an effort.

The food may be on the plate. The machinery to use it is under attack.

Treatment adds its own damage

Chemotherapy for these cancers commonly brings nausea, vomiting, diarrhea, mouth sores, and appetite loss. Each one cuts intake or speeds losses. Diarrhea and vomiting also drain fluids and electrolytes, which deepens weakness and fatigue.

We have written before about how even hospitalized cancer patients routinely miss up to 1,000 calories a day — the tray comes back half-full, day after day, at exactly the moment the body needs more, not less.

Muscle melts quietly

Cancer drives inflammation that breaks down muscle protein — a process separate from simple starvation. This is the territory of cancer cachexia: the body burns its own muscle for fuel even when some food is coming in.

The scan findings in ParcoursDig underline how invisible this can be. Every patient with a moderate frailty score already had sarcopenia — measurable muscle loss — on imaging. About half were below standard muscle-mass thresholds. A person can look "fine" in the waiting room and be running on empty underneath.

The spiral: less reserve, less treatment

Here is where it turns dangerous. A depleted body tolerates chemotherapy poorly. So doses get cut, cycles get delayed, or treatment stops early. Less treatment can mean less cancer control — which means more symptoms, more weight loss, and even less reserve.

Malnutrition is not just a comfort issue. It reaches directly into the dose of medicine a patient can receive.

Why It Matters for Daily Life

Numbers aside, what does nutritional frailty feel like from the inside?

• Stairs become a project. Patients with metastatic disease in ParcoursDig walked 255 meters in six minutes, versus 419 meters for those with localized disease — and could balance on one leg for about 4 seconds, versus 60.
• Meals shrink to bites. The average patient in the program rated their food intake at 7 out of 10 before treatment even began.
• Independence thins out. Getting dressed, cooking, and walking to the mailbox all draw on the same shrinking reserve.
• Hospital time grows. In the surgical study, patients stayed a median of 13 days after major operations.

One caution about a common shortcut: BMI alone can mislead. A patient can hold a "normal" weight on the chart while losing muscle underneath — fluid retention and tumor mass can mask it. That is why this team measured muscle on scans, not just pounds on a scale.

What Did the New Studies Find?

The paper reports two linked studies from the same center.

ParcoursDig (prospective, registered as NCT04478175) tested whether a score-guided support pathway was feasible in real-world practice:

• 30 patients starting first-line chemotherapy for advanced digestive cancers — mostly pancreatic (about 42%), colorectal (33%), and gastric (17%)
• Only patients with a moderate Nutritional Frailty Score (4–7 points) were enrolled — the group judged most able to benefit
• The pathway: dietitian assessments at weeks 0, 4, and 8 with personal calorie and protein targets; nutrition supplements, tube feeding, or IV nutrition when prescribed (fully covered by French health insurance, so cost was not the barrier); physiotherapist testing at weeks 0 and 8 plus a personalized home-exercise plan; and a palliative care doctor's evaluation at weeks 0 and 8
• Success was defined in advance: the program would count as feasible only if at least 80% of patients completed the full schedule

PrePOP (retrospective) looked backward at 48 patients with pancreatic, stomach, or esophageal cancer who received chemotherapy around major surgery, all screened early for malnutrition by a specialized nurse, with supplements for moderate malnutrition and early artificial nutrition for severe cases.

Here is what they found.

Finding #1: Malnutrition was already there before treatment started

In PrePOP, 70.8% of patients were malnourished at baseline — 76% of stomach cancer patients, 71% of pancreatic cancer patients. Of the malnourished, 31% were severely malnourished.

On average, stomach cancer patients had already lost about 10% of their pre-illness body weight, and pancreatic cancer patients about 9% — before the hardest part of treatment began.

The ParcoursDig group looked the same: 70% were malnourished at enrollment. This is not a problem that develops late. Patients arrive depleted.

Finding #2: Malnourished patients needed far more chemotherapy dose reductions

In PrePOP, dose reductions were everywhere — 77% of all patients had at least one. But the burden was not shared equally:

• Severe malnutrition: 90.9% needed a dose reduction
• Moderate malnutrition: 83.3%
• No malnutrition: 53.8%

Serious (grade 3) chemotherapy side effects followed the same pattern: 54.5% in the severely malnourished versus 30.7% in the well-nourished.

And patients without malnutrition completed their full plan of chemotherapy plus surgery 69.2% of the time, versus 42.9% for malnourished patients.

Honest framing: with only 48 patients, these gaps did not reach statistical significance — they are trends, not proof. But they all point the same direction, and they match what larger studies of malnutrition and dose intensity have found before.

Dose reductions touched 77% of surgical patients overall — but 91% of the severely malnourished. Nutrition status and treatment strength are linked.

Finding #3: Fewer than half of patients completed the support program

This is the ParcoursDig headline. The researchers set the bar at 80% completion. What they got was 44.4% — 12 of the 27 patients who could be evaluated.

Even when the researchers loosened the definition — counting patients who got the support eventually, even if visits ran late — completion only reached 63%. Still short.

Three of the 30 enrolled patients died before week 8. Others fell out because their disease progressed or their condition worsened. And the study ran during the second wave of COVID-19, which closed off hospital services and visits.

Finding #4: It was the exercise piece — not the dietitian — that fell apart

The failure breakdown is the most useful part of the study. Among patients who did not complete the program:

• Exercise-support failures (alone or combined with nutrition failures) accounted for about 27–40% of the incomplete cases
• Nutrition-support failures alone accounted for only about 7–10%
• A third of the strict-definition failures were simply visits that happened more than a week late

In other words, patients mostly did see the dietitian. What collapsed was the unsupervised home-exercise plan — advice handed to very sick people, to carry out alone, on their own motivation, in the middle of chemotherapy.

The authors' conclusion is blunt: unsupervised, low-intensity support is not enough. What these patients likely need is supervised, higher-intensity, scheduled help — the kind that shows up, in person, whether motivation does or not.

Finding #5: The gentle program produced no measurable quality-of-life or survival benefit

ParcoursDig found no significant improvement in quality of life or survival from the pathway, and no benefit signal on physical functioning, appetite, or body composition either.

Weight still slipped: a median loss of about 1% of body weight at one month and 3.6% at six months. Muscle surface on scans fell roughly 5–6% in the first eight weeks — in patients who completed the program and in those who did not, alike.

This does not mean support is useless. It means this dose of support — light-touch, largely unsupervised, in a small group of very ill patients — was too weak to move the needle. The authors treat their own study as exploratory, and they say so.

Finding #6: Muscle lost during treatment mattered more than any starting score

In PrePOP, one pattern stood out over time: patients who lost muscle mass during follow-up had a poorer prognosis — while their starting malnutrition status, on its own, was not linked to survival or to surgical complications.

That is a subtle but important shift. A single measurement at diagnosis is a snapshot. What seems to matter more is the trajectory — whether muscle keeps melting month after month. The authors argue for tracking muscle repeatedly during treatment, not just scoring patients once at the door.

Finding #7: Early nutrition help may have blunted the fall — for some

One hopeful thread, offered by the authors with clear caution: by the end of treatment, 41.6% of PrePOP patients had lost more than 10% of their body weight — but the steepest proportional losses appeared in patients who had started out well-nourished, while the malnourished patients who received early supplements or artificial nutrition appeared, for some, to be spared further deterioration.

The key word is appeared. PrePOP had no comparison group receiving no support, so this cannot be proven from these data. It is a hypothesis for the next trial, not a conclusion from this one.

What Good Support Actually Has to Look Like

Read together, these two studies sketch a design spec for supportive care that has a chance of working:

• Start at diagnosis, not at crisis. In these groups, 7 in 10 patients were already malnourished at the starting line. The trial registry for ParcoursDig makes the same point: these problems are reversible early and much harder to reverse late.
• Supervise it. Scheduled, in-person, guided sessions beat advice to exercise at home. The Institut Curie team now points to supervised interval training as the model to test.
• Track muscle, not just weight. Repeat scans or strength tests catch the slide that a scale misses.
• Treat eating problems aggressively and early. Supplements for moderate malnutrition; artificial nutrition without delay when malnutrition is severe.
• Coordinate it. After these studies, the center rebuilt its care around two tracks — joint supportive and palliative follow-up for frail patients with advanced disease, and a structured prehabilitation program before surgery — coordinated by a specialized nurse. That model is now being tested across multiple centers in the POP-UP trial.

And during chemotherapy itself, the unglamorous basics matter daily: managing nausea and diarrhea early, replacing fluids and electrolytes, and keeping the gut working well enough to absorb what is eaten. That supportive layer — hydration, electrolytes, and gut health during treatment — is the ground HuMOLYTE was designed to support, alongside the dietitian-led care above, not instead of it.

What Should Patients and Caregivers Watch For?

Tell your care team promptly if you notice:

• Weight dropping week to week, even "just a few pounds"
• Meals shrinking — feeling full after a few bites, or skipping meals
• Clothes, rings, or a belt suddenly looser
• New weakness: stairs, chairs, or jars becoming harder than they were
• Nausea, vomiting, or diarrhea that lasts more than a day or two
• Mouth sores or swallowing trouble that changes what you can eat
• Drinking much less than usual, dark urine, or dizziness on standing
• A loved one's appetite fading quietly — patients often do not mention it themselves

None of these should be waved off as "just the cancer" or "just the chemo." Each one is a signal the support plan needs adjusting.

Questions to Ask the Oncology Team

1. Has my nutritional status been formally assessed, or only my weight?
2. Have I lost muscle mass, and can that be checked on my scans?
3. Can I be referred to an oncology dietitian before treatment starts — not after I lose weight?
4. What are my personal calorie and protein targets each day?
5. Should I be using oral nutritional supplements? Which kind, and how often?
6. If I cannot eat enough, at what point do we discuss tube feeding or other artificial nutrition?
7. Is there a supervised exercise or prehabilitation program I can join, rather than exercising on my own?
8. Will my chemotherapy dose change if I keep losing weight — and can better nutrition help me stay on full dose?
9. How will we track my nutrition and muscle over time, and how often?
10. Who do I call between visits if eating, drinking, or diarrhea gets worse?

Why This Study Matters

Most cancer research asks whether a new drug works. This study asked a more uncomfortable question: can a good support program actually reach the patients it was built for?

The answer, in this small real-world test, was "not reliably — not yet." And the reasons are instructive. The dietitian visits mostly happened. The food support was free. What failed were the parts that depended on sick patients transporting themselves, motivating themselves, and exercising alone.

That reframes the problem. The bottleneck is not knowledge — teams know malnutrition matters. The bottleneck is delivery: supervision, scheduling, coordination, and follow-up built for people whose energy and health are already spoken for.

The lesson is not that supportive care does not work. It is that supportive care has to be built like treatment itself — dosed, scheduled, supervised, and tracked — or it quietly evaporates.

The center behind the study has already rebuilt its model and is testing the stronger version across multiple hospitals. That is the right response to an honest negative result.

The Bottom Line

A French cancer center scored digestive cancer patients for nutritional frailty, built them a dietitian-led support pathway, and reported the results with unusual candor:

• 71% of surgical patients were malnourished before treatment — and 31% of those were severely malnourished
• 91% of severely malnourished patients needed chemotherapy dose reductions, versus 54% of well-nourished patients
• Only 44% of patients completed the full support program, against the 80% bar the researchers set — 63% even under a generous recount
• The unsupervised exercise component failed far more often than the nutrition component — delivery, not diet advice, was the weak link
• Losing muscle during treatment tracked with a poorer prognosis, more than any single starting measurement

What this does not mean: it does not mean nutrition support is pointless, and it does not mean patients who cannot complete a program have failed. The studies were small (30 and 48 patients), from one hospital, run partly during a COVID wave, and designed to test feasibility — not to prove benefit or harm. The score itself has not yet been validated elsewhere.

What it does mean: if you or someone you love is starting treatment for a digestive cancer, nutrition and muscle deserve a real plan — early, supervised, and measured — and it is reasonable to ask your team, directly, what that plan is.

Frequently Asked Questions

What is a Nutritional Frailty Score?

It is a single score, developed by the team at Institut Curie in France, that combines a patient's age, physical functioning, other medical conditions, and nutritional status to estimate the risk of nutritional decline during treatment. In the study, a moderate score of 4–7 identified the patients offered the support pathway. The score is new and has not yet been validated in other hospitals.

How common is malnutrition in digestive cancers?

Very common. In this study's surgical group, about 71% of patients with pancreatic, stomach, or esophageal cancer were malnourished before treatment, and the chemotherapy group matched that at 70%. The ParcoursDig trial registry notes that more than 60% of advanced digestive cancer patients are malnourished or muscle-depleted at diagnosis.

Did the support program improve survival or quality of life?

No measurable improvement was found in the ParcoursDig study. The program also missed its own feasibility target, which means many patients never received the full intervention — one reason the researchers describe the work as exploratory and are testing a stronger, supervised version.

Why did so few patients finish the program?

The main reasons were disease progression and worsening health, missed or delayed visits, and the study running during a COVID-19 wave that restricted hospital access. The home-exercise component failed far more often than the dietitian component — patients largely kept their nutrition appointments.

Does malnutrition really change chemotherapy treatment?

It appears to. In the surgical study, 77% of all patients needed at least one dose reduction, but the rate was 91% in the severely malnourished versus 54% in patients with no malnutrition, and serious side effects were also more frequent. These were trends in a small study rather than statistical proof, but they match the wider evidence linking malnutrition to poorer treatment tolerance.

What is sarcopenia, and why does it matter here?

Sarcopenia is the loss of muscle mass and strength. Every moderate-score patient in ParcoursDig already had it on imaging, often invisibly — weight and BMI can look acceptable while muscle shrinks. In the surgical study, losing muscle during treatment was linked to a poorer outlook, which is why the authors recommend tracking muscle repeatedly, not just once.

What support is the research team testing now?

A stronger version: supervised, higher-intensity exercise (such as interval training), individualized care plans, and coordinated follow-up, organized into two tracks — supportive and palliative care for frail patients with advanced disease, and structured prehabilitation before surgery. The surgical track is being tested in a multicenter trial called POP-UP.

Should I ask for a dietitian even if I am eating "okay"?

Yes — especially with a digestive cancer. In these studies most patients were already malnourished at diagnosis, including some who did not realize how much ground they had lost. A dietitian assessment at the start of treatment, with personal calorie and protein targets, is the standard this study's team was trying to deliver to everyone.

Can drinking enough and managing diarrhea really affect nutrition?

Yes. Vomiting and diarrhea drain fluids and electrolytes and speed nutrients through the gut before they can be absorbed, which deepens weakness and malnutrition. Reporting gut side effects early — rather than enduring them — protects both hydration and nutrition during chemotherapy.

Does HuMOLYTE treat malnutrition or frailty?

No. HuMOLYTE is a medical food designed to support hydration, electrolyte balance, and gut health during chemotherapy, used under medical supervision. It does not treat malnutrition, rebuild muscle, or replace dietitian-led nutrition care. It fits into the supportive layer around treatment — the daily work of staying hydrated and keeping the gut functioning — while your oncology team manages the nutrition plan itself.

Sources

1. Molina Beltran EE, Gentilhomme L, Vedie AL, et al. "Real-world feasibility of a nutritional frailty score-guided multimodal supportive care pathway in patients with digestive cancer." Scientific Reports, published November 5, 2026.
2. National Cancer Institute. "Nutrition in Cancer Care (PDQ®) — Patient Version." National Cancer Institute, accessed November 2026.
3. Institut Curie. "Prospective Evaluation of a Program for Early Identification of Needs and Multidisciplinary Intervention in Supportive Care in Digestive Oncology (ParcoursDig)." ClinicalTrials.gov, NCT04478175.

---

For more information on how HuMOLYTE can support your gut health during chemotherapy, visit our product page or consult your health care provider.

This blog was reviewed by Dr. Sourabh Kharait.

This blog post is for educational purposes only and is not intended as medical advice. Always consult with your healthcare provider before making changes to your treatment plan, hydration strategies, or diet. The information provided is based on general insights and may not apply to individual circumstances.